Dashboard
Manage Tickers

JNJ JOHNSON & JOHNSON

NYSE jnj.com


$ 188.58 $ 2.45 (1.31 %)    

Thursday, 30-Oct-2025 19:56:19 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.20 nm (nm)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 nm (nm)
TLT $ 90.42 nm (nm)
GLD $ 371.67 $ 7.13 (1.96 %)
$ 189.05
$ 187.56
$ 187.95 x 50
$ 189.50 x 1
-- - --
$ 137.37 - $ 194.48
7,072,517
na
455.48B
$ 0.33
$ 18.13
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-22-2025 09-28-2025 10-Q
2 07-24-2025 06-29-2025 10-Q
3 04-23-2025 03-30-2025 10-Q
4 02-13-2025 12-29-2024 10-K
5 10-23-2024 09-29-2024 10-Q
6 07-25-2024 06-30-2024 10-Q
7 05-01-2024 03-31-2024 10-Q
8 02-16-2024 12-31-2023 10-K
9 10-27-2023 10-01-2023 10-Q
10 10-27-2023 10-01-2023 10-Q
11 07-31-2023 07-02-2023 10-Q
12 04-28-2023 04-02-2023 10-Q
13 02-16-2023 01-01-2023 10-K
14 10-27-2022 10-02-2022 10-Q
15 07-29-2022 07-03-2022 10-Q
16 04-29-2022 04-03-2022 10-Q
17 02-17-2022 01-02-2022 10-K
18 10-29-2021 10-03-2021 10-Q
19 07-29-2021 07-04-2021 10-Q
20 04-30-2021 04-04-2021 10-Q
21 02-22-2021 01-03-2021 10-K
22 10-23-2020 09-27-2020 10-Q
23 07-24-2020 06-28-2020 10-Q
24 04-29-2020 03-29-2020 10-Q
25 02-18-2020 12-29-2019 10-K
26 10-28-2019 09-29-2019 10-Q
27 07-29-2019 06-30-2019 10-Q
28 05-01-2019 03-31-2019 10-Q
29 02-20-2019 12-30-2018 10-K
30 10-31-2018 09-30-2018 10-Q
31 08-02-2018 07-01-2018 10-Q
32 05-01-2018 04-01-2018 10-Q
33 02-21-2018 12-31-2017 10-K
34 11-02-2017 10-01-2017 10-Q
35 08-03-2017 07-02-2017 10-Q
36 05-08-2017 04-02-2017 10-Q
37 02-27-2017 01-01-2017 10-K
38 11-04-2016 10-02-2016 10-Q
39 08-04-2016 07-03-2016 10-Q
40 05-10-2016 04-03-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain
Eli Lilly Extends Lead In $150B Obesity Dr...
10/30/2025 20:04:44

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

johnson--johnson-plans-to-initiate-first-head-to-head-study-comparing-fcrn-blockers-for-patients-with-generalized-myasthenia-gravis
Johnson & Johnson Plans To Initiate First ...
10/29/2025 12:07:04

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch ...

ken-paxton-alleges-johnson--johnson-misled-mothers-on-tylenol-safety
Ken Paxton Alleges Johnson & Johnson Misle...
10/28/2025 17:11:17

Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for ...

Core News & Articles
Johnson & Johnson, Kenvue Sued By Texas At...
10/28/2025 12:53:44

https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-sues-big-pharma-manufacturers-deceptively-marketing-...

Core News & Articles
'US Fires Top Health Official Who Opposed ...
10/28/2025 12:50:58

https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...

johnson--johnson-2-year-data-from-encompass-trial-for-tremfya-for-psoriasis-demonstrates-unmet-needs-strong-preference-for-oral-treatment-options
Johnson & Johnson 2-Year Data From ENCOMPA...
10/27/2025 12:14:13

Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating pat...

johnson--johnsons-tremfya-shows-two-year-results-for-crohns-disease-patients-reports-96-week-data-proving-long-term-benefits-of-tremfya-in-crohns-disease
Johnson & Johnson's TREMFYA Shows Two-Year...
10/27/2025 11:39:07

Johnson & Johnson (NYSE:JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, G...

jj-reports-28-week-data-for-experimental-ulcerative-colitis-treatment-icotrokinra
J&J Reports 28-Week Data for Experimental ...
10/27/2025 11:37:39

Johnson & Johnson (NYSE:JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-c...

reported-friday-johnson--johnson-reports-nipocalimab-achieved-statistically-significant-reduction-in-clinessdai-scores-at-week-24-with-strong-efficacy-and-tolerability-in-sjgrens-disease
Reported Friday, Johnson & Johnson Reports...
10/27/2025 07:19:54

Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study wi...

fda-approves-gsks-withdrawn-blood-cancer-drug-blenrep
FDA Approves GSK's Withdrawn Blood Cancer ...
10/24/2025 14:23:06

FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free...

johnson--johnsons-new-long-term-52-week-data-from-phase-3-iconic-total-study-evaluating-icotrokinra-continues-to-show-potential-with-standout-combination-of-exceptional-skin-clearance-and-favorable-safety-profile-in-once-daily-pill
Johnson & Johnson's New Long-Term 52-Week ...
10/24/2025 12:03:15

In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved ...

freedom-capital-markets-downgrades-johnson--johnson-to-hold-raises-price-target-to-190
Freedom Capital Markets Downgrades Johnson...
10/22/2025 14:56:57

Freedom Capital Markets analyst Ilya Zubkov downgrades Johnson & Johnson (NYSE:JNJ) from Buy to Hold and raises the pric...

johnson--johnsons-inlexzo-plus-cetrelimab-delivers-strong-pre-surgical-results-in-patients-with-muscle-invasive-bladder-cancer-scheduled-for-radical-cystectomy-phase-2b-sunrise-4-study-shows-38-of-patients-treated-with-inlexzo-based-combination-had-no-detectable-cancer-in-the-bladder-prior-to-surgery-data-support-potential-role-of-inlexzo-in-treating-muscle-invasive-bladder-cancer
Johnson & Johnson's INLEXZO Plus Cetrelima...
10/20/2025 13:09:31

https://www.jnj.com/media-center/press-releases/johnson-johnsons-inlexzo-gemcitabine-intravesical-system-plus-cetrelimab-delive...

reported-sunday-johnson--johnson-notes-45-overall-response-rate-72-month-median-duration-of-response-and-68-month-progression-free-survival-with-subcutaneous-amivantamab-in-metastatic-head-and-neck-cancer
Reported Sunday, Johnson & Johnson Notes 4...
10/20/2025 07:18:54

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patientsNew findings from this investigatio...

johnson--johnson-reports-strong-phase-3-results-for-multiple-myeloma-therapy
Johnson & Johnson Reports Strong Phase 3 R...
10/16/2025 17:37:03

Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson...

Core News & Articles
Reported Earlier: 'J&J Faces First UK Laws...
10/16/2025 15:25:41

https://www.reuters.com/sustainability/boards-policy-regulation/jj-faces-first-uk-lawsuits-alleging-its-baby-powder-caused-canc...

johnson--johnson-kenvue-named-in-first-ever-uk-legal-action-over-talc-cancer-claims
Johnson & Johnson, Kenvue Named In First E...
10/16/2025 14:18:35

Johnson & Johnson faces 3,000 UK lawsuits alleging asbestos-contaminated talcum powder caused cancer and concealed risks fo...

johnson--johnson-reportedly-faces-major-uk-lawsuit-over-baby-powder-cancer-risks
Johnson & Johnson Reportedly Faces Major U...
10/16/2025 13:09:59

A legal claim involving 3,000 people has been reportedly filed against Johnson & Johnson (NYSE: JNJ) in the U.K., alleging ...

johnson--johnsons-phase-3-majestec-3-trial-becomes-first-to-show-statistically-significant-progression-free-and-overall-survival-benefit-for-investigational-tecvayli--darzalex-faspro-combo-in-relapsedrefractory-multiple-myeloma-as-early-as-second-line-idmc-recommended-unblinding-the-study-based-on-statistically-significant-results
Johnson & Johnson's Phase 3 MajesTEC-3 Tri...
10/16/2025 12:14:17

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multipl...

scott-bessent-says-us-investment-boom-sustainable-under-trump-the-only-thing-slowing-us-down
Scott Bessent Says US Investment Boom 'Sus...
10/16/2025 12:05:56

U.S. Treasury Secretary Scott Bessent credited the country's investment boom to President Donald Trump's policies on We...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION